PBR Nachrichten

 

According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets. C4 Therapeutics will use its TORPEDO platform for The post Roche and C4 Therapeutics to advance degrader-antibody conjugates research appeared first on Pharmaceutical Business review....

Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan & Lee. Under the agreement, JW Pharmaceutical gains exclusive rights to develop and commercialise the The post Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation appeared first on Pharmaceutical Business review....

The acquisition aims to enhance Everest Medicines' presence and commercial capabilities across key regional markets. Under the deal, Everest Medicines will pay a total consideration of $250m in The post EverSea Medicines to acquire Hasten Biopharmaceuticals appeared first on Pharmaceutical Business review....

The milestone increases Jeito's assets under management to €1.6bn, following the €534m closure of Jeito I in 2021. Continuing the initiative set by Jeito I, Jeito II will The post Jeito Capital secures over $1.2bn for new biopharma investments appeared first on Pharmaceutical Business review....

MineBio will supply RoosterBio's complete platform of products, having already obtained import clearance. This facilitates prompt fulfilment of orders for both research and clinical-grade media solutions focused on The post RoosterBio and MineBio team up to expand MSC solutions access in China appeared first on Pharmaceutical Business review....

Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics, The post Halozyme and Vertex sign deal for Hypercon technology appeared first on Pharmaceutical Business review....

The funding will be used for commercial readiness and the potential US launch of the company's lead product candidate, AD109, pending approval by the US Food and Drug The post Apnimed obtains up to $150m in funds for commercial launch of AD109 appeared first on Pharmaceutical Business review....

The transaction will expand Neurocrine's portfolio in endocrinology and rare diseases via the addition of Soleno's lead product, Vykat XR (diazoxide choline), for Prader-Willi syndrome (PWS). Vykat XR The post Neurocrine to acquire Soleno in $2.9bn transaction appeared first on Pharmaceutical Business review....

The project will enhance Aspect Biosystems' clinical development capabilities and bolster its integrated platform for developing and manufacturing advanced cellular medicines. The investment is in addition to the The post Aspect Biosystems receives funding for cellular medicine project appeared first on Pharmaceutical Business review....

The approval in the European Union (EU) is for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumours are PD-L1 positive, with a combined The post MSD secures EC clearance for Keytruda combination therapy for ovarian cancer appeared first on Pharmaceutical Business review....

This follows the company's signing of a definitive agreement in October 2025 to acquire the business. The deal adds advanced Protein A chromatography capabilities and Amsphere Protein A The post Merck KGaA acquires JSR chromatography business appeared first on Pharmaceutical Business review....

Under the agreement, Biocytogen's fully human antibody discovery platform will be combined with Sihuan Pharmaceutical's capabilities in drug development, manufacturing, and commercialisation. The collaboration will focus on advanced The post Biocytogen and Sihuan partner to advance new therapeutics for weight loss appeared first on Pharmaceutical Business review....

The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial The post Telomir seeks FDA approval for Telomir-1 to treat breast cancer appeared first on Pharmaceutical Business review....

The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins. Molecular glues are an emerging therapeutic modality The post Symeres and Ambagon collaborate for colorectal cancer molecules appeared first on Pharmaceutical Business review....

The FDA approval of Ponlimsi is based on a comprehensive evidence package, including analytical and clinical data showing immunogenicity, safety, and similar efficacy to Prolia. Ponlimsi is approved The post Teva receives FDA approval for Prolia biosimilar appeared first on Pharmaceutical Business review....

The partnership focuses on progressing Cellinfinity BIO's programmes CIB-301 and CIB-350. uBriGene's LVV Turbo platform will provide good manufacturing practice (GMP) lentiviral vector manufacturing, production, process development, and The post uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies appeared first on Pharmaceutical Business review....

The deal is anticipated to close in the second quarter of 2026, subject to standard conditions. The acquisition aims to expand Otsuka's portfolio in the psychiatric and neurological The post Otsuka agrees to acquire Transcend Therapeutics for $1.22bn appeared first on Pharmaceutical Business review....

It is indicated as an adjunct to exercise and diet for improving glycaemic control. The FDA's decision is based on data from the ONWARDS Phase IIIa clinical programme, The post Novo Nordisk receives FDA approval for basal insulin Awiqli appeared first on Pharmaceutical Business review....

The acquisition will provide access to Exl-111, a half-life extended, high-affinity anti-IgE antibody currently in Phase I clinical trials. Designed as an advanced extension of the established biology The post Novartis to acquire Excellergy for $2bn upfront appeared first on Pharmaceutical Business review....

The partnerships aim to apply AI within scientifically validated modelling workflows and define scalable, next-generation approaches throughout the drug development life cycle. The programmes will use Simulations Plus The post Simulations Plus and three pharma companies collaborate on AI-driven drug development appeared first on Pharmaceutical Business review....